Reed's oncologist submitted a request through the FDA's Expanded Access Program, which can allow patients with serious or life-threatening illnesses to receive treatments outside of clinical trials when other options are limited. Daraxonrasib, also known as RMC-6236, is an investigational once-daily oral pill developed by Revolution
Already a subscriber?
Keep reading for $1
Get unlimited, ad-free access to every story.
$1
$4.99
for your first month
- Unlimited access to every TCT story
- No ads
- Read on any device
- Support local, independent journalism
$4.99/month after your first month. Cancel anytime.
Prefer annual billing? $49/year · $4.08/month
More local news